medcelerator · clinician one-pager

First FDA-Approved Implant Treatment for MacTel Eye Disease

Encelto (revakinagene taroretcel-lwey) — encapsulated cell implant for macular telangiectasia type 2

FDA Approved · United States · September 21, 2026

Condition: Macular Telangiectasia Type 2

Who this is for

This is for adults living with idiopathic macular telangiectasia type 2 — and the caregivers who help them — who may be candidates for labelled US Encelto encapsulated cell implants at a vitreoretinal surgery centre after imaging confirms MacTel. It explains the first FDA-approved MacTel therapy, the twin Phase 3 EZ-loss results, surgical and vision-loss honesty, ENCELTOconnect navigation, and why authorised is not funded — without treating completed pivotal research as walk-in enrolment, treating an incomplete centre list as permanent, or importing a US implant. Authorized is not funded.

Next clinical step

This is FDA authorised, not Health Canada authorised. Ask the clinician about US care, a trial, or a Special Access Programme path in United States.

Access doors

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
FDA Expanded Access (Patient Affairs)
US Food and Drug Administration path for a licensed clinician to request an investigational medical product for a patient with a serious or immediately life-threatening condition when no comparable approved therapy is available. This is a request path, not a labelled indication. Authorized is not funded.
https://www.fda.gov/news-events/public-health-focus/expanded-access

Not medical advice. Authorized is not funded. Full piece: https://medcelerator.com/articles/encelto-revakinagene-taroretcel